--- title: "17:12 ET\n \n \n Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS" type: "News" locale: "en" url: "https://longbridge.com/en/news/271844895.md" description: "Kahn Swick & Foti, LLC is investigating the proposed sale of Astria Therapeutics, Inc. (ATXS) to BioCryst Pharmaceuticals, Inc. (BCRX). Shareholders are set to receive $8.55 in cash and 0.59 shares of BioCryst stock for each share of Astria. The firm aims to determine if this offer adequately values the company. Interested parties can contact KSF for more information regarding their legal rights related to the sale." datetime: "2026-01-07T22:13:46.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/271844895.md) - [en](https://longbridge.com/en/news/271844895.md) - [zh-HK](https://longbridge.com/zh-HK/news/271844895.md) generator: "portal-rs" --- # 17:12 ET Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS , /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Astria Therapeutics, Inc. (NasdaqGM: ATXS) to BioCryst Pharmaceuticals, Inc. (NasdaqGS: BCRX). Under the terms of the proposed transaction, shareholders of Astria will receive $8.55 in cash and 0.59 shares of BioCryst common stock for each share of Astria that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (\[email protected\]) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgm-atxs/ to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com. Kahn Swick & Foti, LLC 1100 Poydras St., Suite 960 New Orleans, LA 70163 CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn SOURCE Kahn Swick & Foti, LLC ### Related Stocks - [BCRX.US](https://longbridge.com/en/quote/BCRX.US.md) - [ATXS.US](https://longbridge.com/en/quote/ATXS.US.md) ## Related News & Research - [BioCryst Pharmaceuticals (BCRX), What Is Behind The Fresh Attention Now?](https://longbridge.com/en/news/296688974.md) - [BioCryst Pharmaceuticals (BCRX) Expected to Announce Quarterly Earnings on Wednesday](https://longbridge.com/en/news/294186102.md) - [BioCryst cuts 2026 non-GAAP operating expense outlook to $420 million-$440 million](https://longbridge.com/en/news/291133463.md) - [BioCryst scraps internal drug discovery programs, leans on partnerships to cut costs](https://longbridge.com/en/news/291144353.md) - [BioCryst: Strategic Shift to External Rare-Disease Assets and Cost Discipline Supports Unchanged $32 Price Target and Buy Rating](https://longbridge.com/en/news/291293304.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**